Navigation Links
BiOptix to highlight new 404pi instrument at European symposia
Date:11/1/2012

BOULDER, Colo., AMSTERDAM and VIENNA, Nov. 1, 2012 /PRNewswire/ -- BiOptix today announced that it would be highlighting the new BiOptix 404pi, the first commercially available SPR instrument to incorporate phase-based common path interferometry technology, at the Label Free Technologies Show in Amsterdam from November 1 - 3 as well as at the PEGS Europe Summit on November 6 – 8. 

"At the Label Free and PEGS Europe meetings, BiOptix will unveil new application data that demonstrates the value proposition of the upcoming BiOptix 404pi," noted Ken Wilczek, Vice President of Sales & Marketing for BiOptix.  "We are excited to demonstrate how BiOptix Enhanced or Phase-based SPR differs from standard surface plasmon resonance detection methods in that BiOptix technology combines the high sensitivity of SPR with the high stability and lower noise of common path interferometry—utilizing an internal reference for increased sensitivity."

BiOptix technology allows for the simultaneous monitoring of multiple analytes in a single sample.  This new class of SPR instrumentation from BiOptix has been designed to measure protein/protein and protein-small molecule interactions (down to 100 Da) in a high-throughput 96/384 well platform utilizing 4 parallel channels rather than a single flow cell.     

Surface Plasmon Resonance is an advanced and highly sensitive optical technology that can measure refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

About BiOptix

BiOptix Diagnostics Corporation is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at:  www.bioptix.com


'/>"/>
SOURCE BiOptix
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. BiOptix Participates in Leading Life Sciences Event BioWest 2012
2. BiOptix announces expansion of Board of Directors
3. AGU journal highlights -- 31 August 2012
4. Biomass characterization technology research highlighted in Industrial Biotechnology journal
5. Genetics Society of America’s GENETICS journal highlights for August 2012
6. AGU journal highlights -- 31 July 2012
7. New video series highlights the people who fuel Americas innovation pipeline
8. AGU Journal highlights -- July 16
9. Differences between human twins at birth highlight importance of intrauterine environment
10. Genetics Society of Americas Genetics journal highlights for July 2012
11. Highlighting molecular clues to the link between childhood maltreatment and later suicide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
Breaking Biology Technology: